Search clinical trials for: JNJ-54861911 (25 mg)

Total 690 results

Janssen Pharmaceutical K.K.

Completed

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Terminated

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

Alzheimer Disease

France, Spain, Netherlands, Belgium, Germany, Sweden
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease

Alzheimer's Disease

France, Spain, Netherlands, Belgium, Germany, Sweden
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease

Alzheimer Disease

Spain, Netherlands, Belgium, Sweden
Janssen Pharmaceutical K.K.

Completed

Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia

Alzheimer's Disease

Japan
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)

Alzheimer Disease

France, Belgium, Germany, Spain, Sweden
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery (AXIOMATIC-TKR)

Arthroplasty, Replacement, Knee

Israel, Belgium, Italy, United States, Spain, Hungary, Portugal, Russian Federation, Japan, Turkey, Ukraine, Greece, Poland, Argentina, Brazil, Bulgaria, Canada, South Africa
Sandoz

Completed

To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions

Healthy
Janssen Research & Development, LLC

Withdrawn

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function

Hepatic Impairment
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

Healthy

United States
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

Healthy

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Diabetic Neuropathy

United States
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Janssen Research & Development, LLC

Terminated

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Withdrawn

Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma

Asthma
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Germany, Netherlands
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

Influenza A Virus

Belgium
Janssen Pharmaceutical K.K.

Terminated

A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis

Dermatitis, Atopic

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

Atopic Dermatitis

United States
Zydus Lifesciences Limited

Recruiting

Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

India
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants

Healthy

Japan, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

Low Back Pain | Low Back Pain, Recurrent

United States, Belgium, Canada, Netherlands
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Janssen Research & Development, LLC

Completed

A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

United States, Australia, France, Ukraine, Germany, Israel, Poland, Bulgaria, Romania, Russian Federation, Canada, Netherlands, Belgium, Hungary
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Solid Formulations of JNJ-39393406 in Healthy Male Participants

Healthy

Belgium
Janssen R&D Ireland

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients

Chronic Hepatitis C Infection

Taiwan
Janssen Research & Development, LLC

Withdrawn

A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate

Active Rheumatoid Arthritis; Rheumatoid Arthritis
Janssen-Cilag International NV

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants

Healthy

Belgium
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Hepatic Impairment

Switzerland
Janssen Research & Development, LLC

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery (TEXT-TKR)

VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Belgium, Italy, Malaysia, Latvia, Spain, Turkey, Bulgaria, United States, Lithuania, Russian Federation, Ukraine, Japan, Argentina, Brazil, Canada, Poland
Idorsia Pharmaceuticals Ltd.

Completed

A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

Healthy

United States
Repros Therapeutics Inc.

Completed

Proellex® Pharmacokinetic Bridging Study II (PK)

Healthy

United States
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

Healthy

Belgium
AstraZeneca

Completed

PET Study in Parkinson's Disease Patients

Parkinson's Disease

Sweden
Insmed Incorporated

Completed

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis

United States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland
Idorsia Pharmaceuticals Ltd.

Completed

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany, Australia, Canada, Denmark, Italy, Poland, Serbia, Spain, Switzerland
Novartis Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

Cytopaenia

Japan
NYU Langone Health

Completed

A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

COVID-19

United States
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia (EARLY)

Asymptomatic Amyloid-positive

United States, Canada, United Kingdom, Belgium, Germany, Spain, Japan, Australia, Netherlands, Denmark, Mexico, Finland, Sweden
Novartis Pharmaceuticals

Completed

Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.

Aplastic Anemia

China

3

Subscribe